Search 13,026 Media Articles
Researchers have long known that any single antidepressant drug is little more effective than a placebo in the majority of trials, shown to be less effective than a placebo in some studies, and generally found to be “clinically negligible” with respect to depression remission, while often resulting in severe adverse effects; for example, resulting in a higher percentage of sexual dysfunction than depression remission. However, for nearly twenty years, psychiatry and Big Pharma have told us that while one antidepressant may not work for the majority of patients, in the “real world,” doctors provide patients who have been failed by their initial antidepressant with another antidepressant, and if that fails, still another; and that this real-world treatment is successful for nearly 70% of patients. The problem with this “nearly 70%” story is that the research that has been used to justify it, a 2006 report on the results of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D), has long been disputed by researchers. Moreover, a recent reanalysis of previously undisclosed data reveals that STAR*D, owing to scientific misconduct that dramatically inflated remission rates, may go down in US medical history as one of its most harmful scandals. Even [STAR*D's] fabricated 67% depression remission rate should never have been celebrated. 85% of depressed individuals who go without somatic treatments spontaneously recover within 1 year.
Note: Read more important news articles we've summarized on medical and scientific corruption regarding antidepressants. For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.
While I was out of town on business, I got a call from my dad who told me my husband Woody had been found hanging—dead at age 37. Woody wasn’t depressed and he hadn’t had a history of depression nor any other mental illness. His doctor had prescribed the antidepressant Zoloft to take the edge off. In the following weeks, I started to investigate, to try and understand why my perfectly normal husband had decided to end his life. The only thing that made sense ... Zoloft. Figuring out Zoloft’s dangers completely altered my life’s trajectory, absorbing years of my time. Today, I sit on one of the Food and Drug Administration (FDA) advisory committees that reviews new drugs coming to market. I initially thought that what I was learning about Zoloft was just an isolated issue with antidepressants. But I soon realized it was part of a much bigger, systemic problem with our nation’s drug safety system. The pharmaceutical industry is driven by commercial interests, not public health, and this problem is compounded by a lack of transparency, conflicts of interests, manipulation of clinical trials, and undue corporate influence across the government. Marketing companies ghostwrite pharmaceutical studies for academics who sometimes barely read the papers that get submitted to medical journals, and drug makers then cite these ghostwritten studies as peer-reviewed proof of their products’ safety and efficacy. The revolving door between Big Pharma and the FDA spins faster than the one between the Pentagon and the defense industry.
Note: This guest essay is written by Kim Witczak, a globally renowned advocate for pharmaceutical drug safety and FDA reform. Antidepressants have been found to increase the risk of suicide in some patients. For more along these lines, see concise summaries of deeply revealing news articles on health and Big Pharma corruption from reliable major media sources.
A new study published in JAMA Psychiatry finds that almost everyone will be treated for mental illness at some point in their lives and that their lives are worse in many ways after receiving diagnosis and treatment. About 80% of the population will be hospitalized or receive psychiatric drugs. After treatment, they are more likely to end up poor, unemployed, and receiving disability benefits, and they have worsening social connections. According to the researchers, the likelihood of getting prescribed psychiatric drugs during your lifetime was 82.6% (87.5% for women and 76.7% for men). The likelihood of being hospitalized for mental illness was 29.0% (31.8% for women and 26.1% for men). On average, the 80% who were treated for mental illness were already struggling before treatment. But after treatment, things only got worse. After treatment, “individuals with any mental health disorder were more likely to experience new socioeconomic difficulties, compared with control individuals from the general population,” the researchers write. “During follow-up, they were more likely to become unemployed or receive a disability benefit, to earn lower income, to be living alone, and to be unmarried.” There is copious evidence that antidepressant use leads to worse outcomes in the long term, even after controlling for the severity of depression and other factors. The adverse effects of the drugs lead to worse health outcomes for those taking them, and withdrawal symptoms prevent people from being able to discontinue.
Note: For more along these lines, see concise summaries of deeply revealing news articles on health from reliable major media sources. Then explore the excellent, reliable resources provided in our Health Information Center.
Dr. Ben Goldacre is no slouch when it comes to rooting out the flaws in scientific studies, analyzing clinical trial data and recognizing when it's been manipulated or fudged. But even Goldacre has been fooled by bad science. In ... his forthcoming book, Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients, ... Goldacre describes how he ended up prescribing the antidepressant reboxetine to his patients based on insufficient data. The research overwhelmingly finds the drug to be ineffective, but it was still approved in the U.K. In order to get approval of the drug in Europe, the manufacturer had simply not published its negative data. Seven trials had been conducted comparing reboxetine against a placebo. Only one, conducted in 254 patients, had a neat, positive result, and that one was published in an academic journal, for doctors and researchers to read. But six more trials were conducted, in almost 10 times as many patients. All of them showed that reboxetine was no better than a dummy sugar pill. None of these trials was published. I had no idea they existed. It got worse. The trials comparing reboxetine against other drugs showed exactly the same picture: three small studies, 507 patients in total, showed that reboxetine was just as good as any other drug. They were all published. But 1,657 patients' worth of data was left unpublished, and this unpublished data showed that patients on reboxetine did worse than those on other drugs.
Note: For deeply revealing reports from reliable major media sources on pharmaceutical corruption, click here.
One of the most interesting health research projects of the past decade or so has looked at how exactly exercise makes us feel good. Research shows that there appears to be a clear scientific reason, that we can see at a cellular level. When muscles contract, they secrete chemicals into the bloodstream. Among these chemicals are myokines, which have been referred to as "hope molecules". These small proteins travel to the brain, cross the blood-brain barrier, and act as an antidepressant. They do this by improving our mood, our ability to learn, our capacity for locomotor activity, and protect the brain from the negative effects of ageing. This has been referred to as "muscle-brain cross-talk". They're also responsible for improved metabolism, reduced inflammation, and increased muscle strength. Myokines are not solely responsible for feeling good: exercise also releases neurotransmitters such as dopamine, noradrenaline and serotonin that have a positive impact on our brains. So when you're feeling low, it's tempting to do a Netflix binge, or spend hours scrolling on social media comparing others' lives to yours, and feeling increasingly sad. This is especially true for teenagers. The antidote we know clearly from epidemiology and biology is to just get moving: whether it's joining a team, going for a long walk, or finding a community gym or yoga class. You'll certainly feel more hopeful afterwards.
Note: Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.
Scientific research has long established the healing powers of the outdoors, but now programs promoting regular visits to nature – known as green or nature prescriptions – are nourishing the health of people and parks across the globe. Green prescriptions were pioneered decades ago. In 1982, doctors in Japan began encouraging therapeutic so-called "forest bathing," or Shinrin-yoku, which is now available in 62 certified forest-therapy bases. In New Zealand, green prescriptions ... have become a formal part of the health care system. Canada last year launched its first nationwide green prescription program. Today, 4,000 green prescriptions have been written by over 10,000 physicians ... in all 10 provinces. The benefits of spending time in nature are as established as a centuries-old oak trunk, and include reduced stress and improved sleep, happiness, attention, memory and creativity. In one 2015 study, researchers in Canada found that adding 10 more trees to a city block improved perceived health and well-being as much as increasing people's income by $10,000 or making them seven years younger. Time in nature even impacts the very functioning of our bodies: a study by a professor at University College London found that contact with microbes in the environment strengthens our immune systems, improving the resilience of our skin, airways and guts.
Note: Read more about the fascinating "hope molecules" that get released when we exercise, which can act as a powerful antidepressant for improved mental health.
Risperdal is a billion-dollar antipsychotic medicine with real benefits and a few unfortunate side effects. It can cause strokes among the elderly. And it can cause boys to grow large, pendulous breasts; one boy developed a 46DD bust. Yet Johnson & Johnson marketed Risperdal aggressively to the elderly and to boys while allegedly manipulating and hiding the data about breast development. J&J got caught, pleaded guilty to a crime and has paid more than $2 billion in penalties and settlements. But that pales next to some $30 billion in sales of Risperdal around the world. In 1994, J&J released Risperdal. The Food and Drug Administration said it ... was effective primarily for schizophrenia in adults. Thats a small market. So J&J reinvented Risperdal as a drug for a broad range of problems, targeting everyone from seniors with dementia to children with autism. The company also turned to corporate welfare: It paid doctors and others consulting fees and successfully lobbied for Texas to adopt Risperdal in place of generics. Even though Risperdal wasnt approved for the elderly, J&J formed a sales force called ElderCare. The F.D.A. protested and noted that there were an excess number of deaths among the elderly who took the drug. At the same time, J&J ... began peddling the drug to pediatricians, so that by 2000, more than one-fifth of Risperdal was going to children and adolescents. In 2003, the company had a back to school marketing campaign for Risperdal. By 2004 Risperdal was a $3-billion-a-year drug.
Note: For more, see this NY Times article and this one. For more along these lines, see concise summaries of deeply revealing big pharma corruption news articles from reliable major media sources.
The pharmaceutical group GlaxoSmithKline has been fined $3bn (1.9bn) after admitting bribing doctors and encouraging the prescription of unsuitable antidepressants to children. The company encouraged sales reps in the US to mis-sell three drugs to doctors and lavished hospitality and kickbacks on those who agreed to write extra prescriptions. The company admitted corporate misconduct over the antidepressants Paxil and Wellbutrin and asthma drug Advair. GSK also paid for articles on its drugs to appear in medical journals and "independent" doctors were hired by the company to promote the treatments. Paxil which was only approved for adults was promoted as suitable for children and teenagers by the company despite trials that showed it was ineffective. Children and teenagers are only treated with antidepressants in exceptional circumstances due to an increased risk of suicide. The second drug to be mis-sold was Wellbutrin another antidepressant aimed only at adults. The prosecution said the company paid $275,000 to Dr Drew Pinsky, who hosted a popular radio show, to promote the drug on his programme, in particular for unapproved uses. US attorney Carmin Ortiz said: "The sales force bribed physicians to prescribe GSK products using every imaginable form of high-priced entertainment, from Hawaiian vacations [and] paying doctors millions of dollars to go on speaking tours, to tickets to Madonna concerts." Despite the large fine, $3bn is far less than the profits made from the drugs.
Note: In February 2016, GlaxoSmithKline was fined another $53 million by the UK for preventing generic competition. The list of huge fines to top drug companies includes five fines of over $1 billion and dozens over $100 million. How can we trust these companies on the safety and reliability of their products?
No one foresaw ... the shocking extent to which the internet would change the terms of trade between corporations and society. One of the world's largest drug companies [was] the first victim. Britain's GlaxoSmithKline, the world's second-largest pharma, denied any wrongdoing, but agreed to pay $2.5m ... for concealing evidence of its antidepressant Seroxat's potential for harming children, while doing them no measurable good. Infinitely more frightening ... this pharma had the backing of institutions that we, the public, rely on to protect us from poisoning by prescription. The Royal College of Psychiatrists had insisted only a year earlier that 'there is no evidence that antidepressant drugs can cause dependence syndromes'. It was really the internet that allowed public health activists to do an end run around GSK's and the medical authorities' denials of the drug's risks. An explosion of websites dedicated to vivid accounts of antidepressant reactions told these campaigners about hundreds of thousands affected by a problem that officially did not exist. Health activists in Britain and America have uncovered the core of pharma might. In both countries, clinical drug tests are paid for by the pharmas, who tweak the trials' design for the best possible results. Until recently, only the most favourable findings got published in the 20,000-odd biomedical journals, many of them dependent on pharmas for funding. The drugs are approved for marketing by regulators, whose salaries are mostly financed by the subjects of their evaluations. The medicines are then prescribed by doctors routinely courted with pharma gifts ... meant to persuade them to change their prescribing habits.
Note: For a two-page summary with lots more reliable information on major health cover-ups by a doctor who was editor-in-chief of one of the most pretigious medical journals in the world, click here.
Antidepressants raise the risk of suicide while also giving people the means to kill themselves, scientists have warned, after discovering thousands of inquests linked to the drugs. Psychologists at the University of East London (UEL) analysed media reports of nearly 8,000 coroners' inquests in England and Wales between 2003 and 2020, in which antidepressants were mentioned. They found the drugs were linked to 2,718 cases of hanging and 2,329 overdoses, of which 933 people had overdosed on antidepressants themselves. A further 2,083 had been struck by a train, tube, lorry or other vehicle, had jumped or fallen to their death, drowned, shot themselves, or been involved in a fire or electrocution. Study author Dr John Read ... said: "Not only do antidepressants not reduce suicidality, but they also actually increase it for many, and for some they provide the mechanism for killing oneself." The research, ... concluded: "If the goal is to prevent suicide then clearly they are not working for thousands of people." Around one in six of the adult population takes antidepressants each year. In 2018, Prof Read surveyed nearly 1,500 people taking antidepressants and found that 50 per cent reported suicidal thoughts after starting the drugs. Recent studies have also called into question the benefits of antidepressants. Last year, University College London (UCL) concluded that depression is not caused by a chemical imbalance of serotonin and argued that life events were a larger factor.
Note: Antidepressants are some of the most commonly prescribed medications, yet their significant risks are often withheld from public debate. Furthermore, an in-depth investigation reveals the glaring conflicts of interest and financial ties to corporate drugmakers that are behind many studies marketing clinical antidepressants as safe.
As of 2018, nearly one in eight Americans use antidepressants. Unfortunately, more than a third of patients are resistant to the mood-improving benefits of medicine’s best antidepressant drugs. These people are not completely out of options. There are chemicals already out there that can restore their mood balance, and in some cases, even save their lives. Chemicals such as lysergic acid diethylamide (LSD), psilocybin (magic mushrooms) and dimethyltryptamine (DMT) are more accurately called “serotonergic psychedelics” among the neuroscience community. At the correct doses, psychedelics are well tolerated, producing only minor side effects such as transient fear, perception of illusions, nausea/vomiting or headaches. These fleeting side effects pale in comparison to the severity of commonly prescribed antidepressants, which include dangerous changes in heart rate and blood pressure, paradoxical increases in suicidality, and withdrawal symptoms. As far as outcomes go, psychedelics in combination with psychotherapy are remarkably efficient at treating depression. Compared to selective serotonin reuptake inhibitors, or SSRIs, the current gold standard in antidepressant medication, psychedelics have a faster effect on patients, sometimes effective with only a single therapy session. Psychedelics also have a longer-lasting effect than an SSRI regimen. A 2015 study ... demonstrated that past history of psychedelic use decreases the odds of suicidal thoughts or actions over the course of a lifetime.
Note: Read more about the healing potentials of psychedelic medicine. Explore more positive stories like this in our comprehensive inspiring news articles archive focused on solutions and bridging divides.
In 2001, a "landmark" study published in the prestigious Journal of the American Academy of Child and Adolescent Psychiatry purported to show the safety and effectiveness of using a common antidepressant to treat adolescents. The original published findings were biased and misleading. Known as Study 329, the randomised controlled trial ... was funded by SmithKline Beecham now GlaxoSmithKline (GSK) the manufacturer of paroxetine. The research has been repeatedly criticised, and there have been numerous calls for it to be retracted. To re-analyse the evidence of effectiveness and safety of paroxetine, we used documents posted online by GSK. We also had access to other publicly available documents and individual participant data. We found that paroxetine [Paxil] was no more effective than a placebo, which is the opposite of the claim in the original paper. We also found significant increases in harms with both paroxetine and imipramine, [another antidepressant]. Compared with the placebo group, the paroxetine group had more than twice as many severe adverse events, and four times as many psychiatric adverse events, including suicidal behaviours and self-harm. And the imipramine group had significantly more heart problems. Our re-analysis ... identified ten strategies used by researchers in this clinical trial to minimise apparent harms. More importantly, our findings show influential peer-reviewed research published in leading medical journals can be seriously misleading.
Note: We all know that clinical trial are skewed when they are sponsored by drug companies, but here is undeniable proof of this published in the UK's most respected medical journal. See this key study on the website of the British Medical Journal. Then don't miss that amazing documentary "Bought" available for free viewing.
Dr. David Healy is an internationally renowned psychiatrist, psychopharmacologist, scientist, and author. He was responsible for submitting the key document that led to New York State's successful fraud action against GlaxoSmithKline. [Q.] Youve written at your blog that evidence-based medicine and RCTs [random controlled trials] are ... simply not the answer to determining cause and effect, [because] theyre quite likely to hide rather than reveal a problem like antidepressant induced suicidality. How in fact do RCTs hide such information? [Dr. Healy:] There are ... specific problems like miscoding, where suicidality becomes nausea or emotional lability or even treatment non-responsiveness. There is also the problem of mislocation – patients on placebo end up being given problems they never had – and of nonexistent patients, who dont of course have adverse events. Beyond that, there are more sophisticated tricks that companies can and do play – such as claiming that increased rates of a problem on a drug are not really evidence of an increase in rates if the data are not statistically significant. In this way, companies have hidden many more heart attacks on Vioxx and Avandia or suicidal acts on SSRIs than have been hidden by miscoding or mislocation. When it comes to adverse events, trials almost never get the right answer. The deeper problem ... is the combination of product patents, prescription-only status, and the use of clinical trials as a means of determining efficacy – in particular, when the data from those trials are not made available. This creates a perfect product ... which industry can manipulate to mean whatever they want them to mean.
Note: Dr. Healy is the author of more than 150 peer-reviewed articles and 20 books. For an excellent article going further into Dr. Healy's amazing work, click here. For deeply revealing reports from reliable major media sources on health corruption and manipulations, click here.
Do antidepressants work? "The difference between the effect of a placebo and the effect of an antidepressant is minimal for most people," says Harvard scientist Irving Kirsch. Kirsch's views are of vital interest to the 17 million Americans who take the drugs, including children as young as six and to the pharmaceutical industry that brings in $11.3 billion a year selling them. Irving Kirsch is the associate director of the Placebo Studies Program at Harvard Medical School. He says that his research challenges the very effectiveness of antidepressants. Kirsch's specialty has been the study of the placebo effect: the taking of a dummy pill without any medication in it that creates an expectation of healing that is so powerful, symptoms are actually alleviated. Kirsch, who's been studying placebos for 36 years, says "sugar pills" can work miracles. Kirsch: Placebos are great for treating a number of disorders: irritable bowel syndrome, repetitive strain injuries, ulcers, Parkinson's disease. Even traumatic knee pain. In this clinical trial some patients with osteoarthritis underwent knee surgery, while others had their knees merely opened and then sewn right back up. In terms of walking and climbing, the people who got the placebo actually did better than the people who got the real surgery. And that lasted for a year. At two years after surgery, there was no difference at all between the real surgery and the sham surgery. It's not all in your head because the placebos can also affect your body.
Note: For key reports from reliable sources on health issues, click here.
Antidepressants ... may be no better than dummy pills for people with mild or moderate depression, according to a study that suggests 70 percent of patients wouldnt benefit from the drugs. In a review of six trials of antidepressants involving more than 700 patients published yesterday in the Journal of the American Medical Association, researchers led by Jay Fournier at the University of Pennsylvania found the drugs helped only those patients with the most severe depression. Doctors, policy makers and sufferers should be made aware that theres little evidence to show the treatments will benefit patients with less severe symptoms, the authors said. This important feature of the evidence base is not reflected in the implicit messages present in the marketing of these medications to clinicians and the public, they said. The researchers combined data from six trials. The drugs had a nonexistent to negligible effect on patients with mild, moderate and severe symptoms, compared with those who took a placebo, according to a commonly used scale used to measure the disorder. The pills had a large effect on patients with very severe symptoms, the study found.
Note: For a treasure trove of important reports on corruption regarding major health issues, click here.
The World Health Organization estimates that ... depression and anxiety rose by more than 25 percent in the first year of the COVID pandemic, adding to the nearly one billion people who were already living with a mental disorder. One of the principal ways mental health disorders are thought to manifest is through severed connections between neurons — the winding, spindly cells in our brain and throughout our body essential for interpreting info from the external environment. Certain antidepressant drugs seem to work by increasing serotonin levels, an important neurotransmitter that the brain uses to send signals between neurons. They can help regrow neuronal connections ... only the effect seems to be slower, less dramatic [and] can come with significant drawbacks. In contrast, psychedelics can promote this kind of regrowth in as little as 24 hours, often less. Many experts believe psychedelic drugs ... act like Miracle Grow for neurons, helping them flourish like a dense forest. Pretty much the only reason drugs have a psychoactive effect on us at all is because they closely resemble chemicals our body already produces. Most psychedelic drugs like LSD, DMT and psilocybin are structurally similar to serotonin, so they can act on serotonin receptors, but in a slightly different way. You can think of it like clumsily-made lockpicks that still work in a lock designed for a specific key. But even the slight differences can have profound effects, specifically, altered perception of time and space and intensified colors and sounds.
Note: Read more on the healing potentials of psychedelic medicine. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.
We urgently need a national debate about guns. But we also urgently need a national debate about the epidemic of mood-altering drugs being prescribed to young Americans. Mass shooters in the United States tend to be young, obsessive, male loners and many have been prescribed psychoactive drugs. For example, Eric Harris, one of the two shooters at Columbine High School in Columbine, Colorado, in 1999—which ushered in the current spate of mass shootings—was on the psychotropic drug Luvox. Prescribing information for the antidepressant says, “Close supervision of patients and in particular those at high risk should accompany drug therapy.” Jeff Weise, who fatally shot his grandfather, his grandfather’s girlfriend, and then seven others at the Red Lake Senior High School in Minnesota in 2005, was on the well-known antidepressant Prozac. Two years later, Cho Seung-Hui, who perpetrated the Virginia Tech mass shooting, also was found to be on psychoactive antidepressants. Jeanne Stolzer, associate professor of child and adolescent development at the University of Nebraska-Kearney, observes that “despite the multitude of international drug regulatory warnings on all classifications of psychiatric medications citing adverse reactions such as suicidal ideation, homicidal ideation, violence, and psychosis, not one local, state, or federal commission has investigated the correlation between the mass shootings in America and the use of psychiatric medications.”
Note: Although Epoch Times is often deemed as a controversial media platform, this article raises legitimate questions on an important topic seldom discussed. Read a revealing article that investigates the alarming adverse events associated with common mood-altering medications prescribed for those struggling with mental illness. For more on this concerning trend, consider exploring an in-depth article written by an anonymous doctor who reveals the decades of evidence showing how adverse reactions from psychiatric drugs can manifest as both suicides and homicides.
Prozac, the bestselling antidepressant taken by 40 million people worldwide, does not work and nor do similar drugs in the same class, according to a major review released today. The study examined all available data on the drugs, including results from clinical trials that the manufacturers chose not to publish at the time. The trials compared the effect on patients taking the drugs with those given a placebo or sugar pill. When all the data was pulled together, it appeared that patients had improved - but those on placebo improved just as much as those on the drugs. The only exception is in the most severely depressed patients, according to the authors - Prof Irving Kirsch from the department of psychology at Hull University and colleagues in the US and Canada. But that is probably because the placebo stopped working so well, they say, rather than the drugs having worked better. "Given these results, there seems little reason to prescribe antidepressant medication to any but the most severely depressed patients, unless alternative treatments have failed," says Kirsch. "This study raises serious issues that need to be addressed surrounding drug licensing and how drug trial data is reported." The paper, published today in the journal PLoS (Public Library of Science) Medicine, is likely to have a significant impact on the prescribing of the drugs. The National Institute for Health and Clinical Excellence already recommends that counselling should be tried before doctors prescribe antidepressants.
Note: For many key reports on health issues from reliable sources, click here.
Medical experts and politicians have called for the amount of antidepressants being prescribed to people across the UK to be reduced in an open letter to the government. The letter coincides with the launch of the all-party parliamentary group Beyond Pills, which aims to reduce what it calls the UK healthcare system’s over-reliance on prescription medication. A total of 8.6 million patients in England were prescribed antidepressants in 2022-23, with the amount having almost doubled since 2011. Published in the British Medical Journal ... the letter says: “Rising antidepressant prescribing is not associated with an improvement in mental health outcomes at the population level, which, according to some measures, have worsened as antidepressant prescribing has risen.” The letter goes on to say that reducing the rate of antidepressant prescriptions could be achieved through measures that includes stopping the prescribing of antidepressants for mild conditions, and funding and delivering a national 24-hour prescribed drug withdrawal helpline ... to help those experiencing withdrawal symptoms from prescription medication. [Former chief executive of NHS England, Nigel] Crisp said: “The high rate of prescribing of antidepressants over recent years is a clear example of over-medicalisation, where patients are often prescribed unnecessary and potentially harmful drugs instead of tackling the root causes of their suffering, such as loneliness, poverty or poor housing.
Note: Antidepressants are some of the most commonly prescribed medications, yet their significant risks are often withheld from public debate. For more along these lines, see concise summaries of deeply revealing news articles on health and Big Pharma corruption from reliable major media sources.
The US Food and Drug Administration approved Janssen Pharmaceuticals Inc.'s esketamine on Tuesday for treatment-resistant depression; the drug is the chemical cousin of ketamine, the powerful anesthetic that has been used illegally as the club drug Special K. It will be sold as Spravato. It's for patients who have tried at least two other medications without success, and it should be taken with an oral antidepressant. "There has been a longstanding need for additional effective treatments for treatment-resistant depression, a serious and life-threatening condition," Dr. Tiffany Farchione, acting director of the Division of Psychiatry Products at the FDA's Center for Drug Evaluation and Research, said. Spravato is a nasal spray administered by an approved health care provider in a doctor's office or a medical clinic. It may also be self-administered but only under the supervision of a care provider and cannot be taken home. Depending on the severity of the patient's depression, it is given either once a week or once every other week. The drug is rapidly acting, so it starts working faster than other antidepressants, according to Janssen. It works by restoring brain cells in patients with treatment-resistant depression. Currently available treatments for major depression are ineffective in 30% to 40% of patients. The drug was designated as a breakthrough therapy in 2013, a status intended to "expedite the development and review of drugs for serious or life-threatening conditions," the FDA said at the time.
Note: For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources.
Hallucination-inducing drugs like magic mushrooms could be about to break big pharmas stranglehold on the hugely lucrative market for antidepressants, according to the head of the worlds first centre for psychedelic research. Antidepressant prescriptions have doubled in England in a decade with around seven million adults taking the drugs, and the global market is predicted to be worth $15.9bn (12.5bn) by 2023. At Imperial College London, Dr Robin Carhart-Harris is leading one of the first trials to test how therapy using psilocybin mushrooms, which are currently banned in the UK, compares to leading antidepressants. While he wont prejudge the results of the study, he says participants describe a cathartic emotional release with psilocybin therapy the polar opposite of antidepressants, which patients complain leave their emotions, whether positive or negative, blunted. It is the first of many studies planned under the banner of the new Centre for Psychedelic Research at Londons Imperial College. Dr James Rucker is another of those researching the potential benefits of psychedelics ... at Kings College London. The Kings team are launching two trials, one looking at whether psilocybin therapy can help people whose depression is resistant to treatment with conventional antidepressants. He says it was possible the drug could be licensed in five years.
Note: For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources.
Psychologist and best-selling author Shawn Achor has made a career studying the science of happiness. "Scientifically, happiness is a choice," Achor says. He explains that research has shown you can rewire your brain to make yourself happy by practising simple happiness exercises. Achor says in just 21 days, the exercises can transform a pessimist into an optimist. And within 30 days, those habits change the neuropathways of our brains and turn us into lifelong optimists. These six daily happiness exercises are proven to make anyone, from a 4-year old to an 84-year old, happy, or simply happier, Achor says: 1. Gratitude Exercises. Write down three things you're grateful for that occurred over the last 24 hours. They don't have to be profound. 2. The Doubler. Take one positive experience from the past 24 hours and spend two minutes writing down every detail about that experience. As you remember it, your brain labels it as meaningful and deepens the imprint. 3. The Fun Fifteen. Do 15 minutes of a fun cardio activity, like gardening or walking the dog, every day. The effects of daily cardio can be as effective as taking an antidepressant. 4. Meditation. Every day take two minutes to stop whatever you're doing and concentrate on breathing. 5. Conscious act of kindness. At the start of every day, send a short email or text praising someone you know. 6. Deepen Social Connections. Spend time with family and friends.
Note: The three-minute video at the link above link has some good ideas on achieving greater happiness. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.
In a rare move, the Justice Department on Tuesday announced that it had charged a former vice president and top lawyer for the British drug giant GlaxoSmithKline with making false statements and obstructing a federal investigation into illegal marketing of the antidepressant Wellbutrin for weight loss. “This is absolutely precedent-setting — this is really going to set people’s hair on fire,” said Douglas B. Farquhar, a Washington lawyer. “This is indicative of the F.D.A. and Justice strategy to go after the very top-ranking managing officials at regulated companies.” The indictment accuses the Glaxo official, Lauren C. Stevens of Durham, N.C., of lying to the Food and Drug Administration in 2003, by writing letters, as associate general counsel, denying that doctors speaking at company events had promoted Wellbutrin for uses not approved by the agency. Ms. Stevens “made false statements and withheld documents she recognized as incriminating,” including slides the F.D.A. had sought during its investigation, the indictment stated. The company was cooperating fully with a federal investigation into allegations of illegal sales and marketing of Wellbutrin. Last year, it set aside $400 million to resolve the case, which is still pending. Two weeks ago, in an unrelated case, GlaxoSmithKline agreed to pay $750 million to the government to settle civil and criminal complaints that it sold tainted or ineffective products from a large manufacturing facility in Puerto Rico.
Note: Even with fines in the hundreds of millions of dollars assessed to many of the large pharmaceuticals, why isn't more being done? See what one of the top doctors in the US revealed about corruption in health care at this link.
GlaxoSmithKline, the British drug giant, has agreed to pay $750 million to settle criminal and civil complaints that the company for years knowingly sold contaminated baby ointment and an ineffective antidepressant — the latest in a growing number of whistle-blower lawsuits that drug makers have settled with multimillion-dollar fines. Altogether, GlaxoSmithKline sold 20 drugs with questionable safety that were made at a huge plant in Puerto Rico that for years was rife with contamination. Cheryl D. Eckard, the company’s quality manager, asserted in her whistle-blower suit that she had warned Glaxo of the problems but the company fired her instead of addressing them. Among the drugs affected were Paxil, an antidepressant; Bactroban, an ointment; Avandia, a troubled diabetes drug; Coreg, a heart drug; and Tagamet, an acid reflux drug. Justice Department officials announced the settlement in a news conference Tuesday afternoon in Boston, saying a $150 million payment to settle criminal charges was the largest such payment ever by a manufacturer of adulterated drugs. The outcome also provides $600 million in civil penalties. The share to the whistle-blower will be $96 million, one of the highest such awards in a health care fraud case.
Note: For key reports from major media sources on corporate corruption and criminality, click here.
Doctors and patients are being misled about the effectiveness of some drugs because negative trial results are not published, experts have warned. Writing in the British Medical Journal, they say that pharmaceutical companies should be forced to publish all data, not just positive findings. The German team give the example of the antidepressant reboxetine, saying publications have failed to show the drug in a true light. Reboxetine (Edronax), made by Pfizer, is used in many European countries, including the UK. But its rejection by US drug regulators raised doubts about its effectiveness, and led some to hunt for missing data. This is not the first time a large drug company has come under fire about its published drug trial data. Pharmaceutical giant GlaxoSmithKline (GSK) was criticised for failing to raise the alarm on the risk of suicidal behaviour associated with its antidepressant Seroxat. GSK has also been forced to defend itself over allegations about hiding negative data regarding another of its drugs, Avandia, which is used to treat diabetes. "Our findings underline the urgent need for mandatory publication of trial data," [the researchers] say in the BMJ. They warn that the lack of all information means policy makers are unable to make informed decisions. In the US, it is already a requirement that all data - both positive and negative - is published.
Note: For a powerful summary of government/corporate corruption in the pharmaceutical industry by a respected former editor of a major medical journal, click here.
A breathing-based meditation practice known as Sudarshan Kriya yoga helped alleviate severe depression in people who did not fully respond to antidepressant treatments, reports a new study published in the Journal of Clinical Psychiatry. Researchers found significant improvement in symptoms of depression and anxiety in medicated patients with major depressive disorder (MDD) who participated in the breathing technique compared to medicated patients who did not partake. More than half of the 41 million Americans who take antidepressants do not fully respond. Add-on therapies are often prescribed to enhance the effects of the drugs in these patients, but they typically offer limited additional benefits and come with side effects that can [prolong] the depressive episode. The meditation technique ... includes a series of sequential, rhythm-specific breathing exercises that bring people into a deep, restful, and meditative state: slow and calm breaths alternated with fast and stimulating breaths. In past studies, the practice has demonstrated a positive response in patients with milder forms of depression, depression due to alcohol dependence, and in patients with MDD; however, there are no clinical studies investigating its use for depression in an outpatient setting. Past studies suggest that yoga and other controlled breathing techniques can potentially adjust the nervous system to reduce stress hormones.
Note: Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.
When the drug industry came under fire last summer for failing to disclose poor results from studies of antidepressants, major drug makers promised to provide more information about their research on new medicines. But nearly a year later, crucial facts about many clinical trials remain hidden. Eli Lilly and some other companies have posted hundreds of trial results on the Web and pledged to disclose all results for all drugs they sell. But other drug makers, including Merck and Pfizer, release less information and are reluctant to add more, citing competitive pressures. As a result, doctors and patients lack critical information about important drugs ... and the companies can hide negative trial results by refusing to publish studies, or by cherry-picking and highlighting the most favorable data. GlaxoSmithKline agreed to pay $2.5 million to settle a suit ... alleging that Glaxo had hidden results from trials showing that its antidepressant Paxil might increase suicidal thoughts in children and teenagers. Federal laws require the disclosure of all trials and trial results to the F.D.A. But companies are not required to disclose trial results to scientists or the public. Under pressure from the editors of medical journals, the major drug companies in January agreed to expand the number of trials registered on clinicaltrials.gov. Three companies have filed only vague descriptions of many studies, often failing even to name the drugs under investigation. For example, Merck describes one trial as a "one-year study of an investigational drug in obese patients."
A psychedelic drink used for centuries in healing ceremonies is now attracting the attention of biomedical scientists as a possible treatment for depression. Researchers from Brazil last month published results from the first clinical test of a potential therapeutic benefit for ayahuasca, a South American plant-based brew. The work forms part of a renaissance in studying the potential therapeutic benefits of psychedelic or recreational drugs research that was largely banned or restricted worldwide half a century ago. Ketamine, which is used medically as an anaesthetic, has shown promise as a fast-acting antidepressant; psilocybin, a hallucinogen found in magic mushrooms, can help to alleviate anxiety in patients with advanced-stage cancer; MDMA (ecstasy) can alleviate post-traumatic stress disorder; and patients who experience debilitating cluster headaches have reported that LSD eases their symptoms. Ayahuasca, a sacramental drink traditionally brewed from the bark of a jungle vine (Banisteriopsis caapi) and the leaves of a shrub (Psychotria viridis) ... has been studied by anthropologists, social scientists and theologians, but clinical research on ayahuasca has been limited to observation of its effects in mice and rats, and in healthy human volunteers, including brain-imaging studies and retrospective surveys of past use. Further trials are under way.
Note: Are the healing potentials of mind altering drugs finally starting to receive honest mainstream attention?
While [Ketamine] has been used as an anesthetic for decades, small studies at prestigious medical centers like Yale, Mount Sinai and the National Institute of Mental Health suggest it can relieve depression in many people who are not helped by widely used conventional antidepressants like Prozac or Lexapro. And the depression seems to melt away within hours, rather than the weeks typically required for a conventional antidepressant. Pharmaceutical companies hope to [develop] drugs that work like ketamine but without the side effects, which are often described as out-of-body experiences. Some doctors and patients are not waiting for the pharmaceutical industry. Because ketamine has long been approved for anesthesia, doctors are allowed to use it off-label to treat depression. There is clearly a need for new drugs. Almost half of depressed patients are not being treated adequately by existing drugs, said Dr. Sheldon H. Preskorn, a professor of psychiatry at the University of Kansas School of Medicine-Wichita. That, he said, is because virtually all the antidepressants used in the last 60 years work essentially the same way. Ketamine would represent a new mechanism of action. Synaptic connections that help us to cope seem to grow back, said Dr. John H. Krystal, chairman of psychiatry at Yale and a pioneer in the study of ketamine for depression.
Note: A 2012 NPR story provides more detail about the ketamine research done at Yale to treat depression. Could this put a stop to the thousands of horror stories involving conventional antidepressants?
For the second time in two months, The Journal of the American Medical Association says it was misled by researchers who failed to reveal financial ties to drug companies. The latest incident, disclosed in letters to the editor and a correction in Wednesday's journal, involves a study showing that pregnant women who stop taking antidepressants risk slipping back into depression. Most of the 13 authors have financial ties to drug companies including antidepressant makers, but only two of them revealed their ties when the study was published in February.
Note: To understand how the drug companies manipulate results and even exert tremendous influence over the U.S. Congress, see http://www.WantToKnow.info/healthcoverup
It's the conundrum that faces all television personalities broadcasting live: how to deal with hecklers trying to disrupt the show. Do you ignore the perpetrators? Do you try to reason with them? Or do you do what the American comic and talk show host Bill Maher did - jump into the audience, threaten the hecklers with an "ass kicking" and scream "Get the fuck out of my building!" In one of the more unconventional displays of audience interaction on US television in recent years, that is now doing hot trade as a clip on YouTube, Maher reacted to the interruptions of hecklers in his studio audience with the memorable words: "Do we have some fucking security in this building?" He then tore off his lapel microphone and stormed off the stage and up to some protesters wielding "expose the 9/11 cover-up" banners. It was at that point during a panel discussion on his HBO show, Real Time With Bill Maher, that the nature of the comic's difficulties with an element of his audience became clear. Maher is a darling of the US liberal intelligentsia for his brand of Bush-bashing and anti-religious pedantry. But the one point over which he will not bash the Bush administration is the events of September 11 2001. He does not agree with 9/11 conspiracy theorists, or Truthers as they call themselves, that the Bush administration brought down the Twin Towers in a controlled explosion. The trouble started a few weeks ago when Maher launched a verbal assault on air against the Truthers, calling them "crazy people". He advised the conspiracy theorists, who had been demonstrating outside his studio, to visit their doctor to ask whether the antidepressant Paxil was right for them. In 2002 ABC ended its relationship with him over comments he made in his former show, Politically Incorrect, about the 9/11 hijackers.
Note: To watch Bill Maher's performance on YouTube, click here. For a concise summary of reliable reports from major media sources which raise many unanswered questions about what really happened on 9/11, click here.
Exposure to dirt may be a way to lift mood as well as boost the immune system, UK scientists say. Lung cancer patients treated with "friendly" bacteria normally found in the soil have anecdotally reported improvements in their quality of life. Mice exposed to the same bacteria made more of the brain's "happy" chemical serotonin, the Bristol University authors told the journal Neuroscience. A lack of serotonin is linked with depression in people. The scientists say more work is now needed to determine if the bacterium Mycobacterium vaccae has antidepressant properties. Lead researcher Dr Chris Lowry said: "These studies help us understand how the body communicates with the brain and why a healthy immune system is important for maintaining mental health. They also leave us wondering if we shouldn't all spend more time playing in the dirt." The work could also help experts' understanding of why an imbalance in the immune system leaves some individuals vulnerable to mood disorders like depression, he added.
